Obesity, Overweight
Conditions
Keywords
Pu' er Tea, glucose and lipid metabolism, intestinalflora
Brief summary
To study the effect of Pu'er tea in overweight / obese patients with blood glucose or abnormal lipid metabolism. Compared with the effect of two Pu'er tea with different tea fuscin content in improving glucose and lipid metabolism, to investigate the mechanisms of bile acid metabolism and intestinal flora regulation. In a prospective randomized controlled clinical study, 90 patients were divided into study group (3T Pu'er tea group, 45 patients) and control group ( traditional Pu'er tea group,45 patients). Before and after the treatment(0day, 12 weeks, 52 weeks) patients' markers of glucose and lipid metabolism were examined and compared.
Interventions
OTHER3T Pu'er tea
Two types of Pu-erh tea with different levels of theabrownin content.
Sponsors
Longgang District People's Hospital of Shenzhen
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
The A、B should be simultaneously met, or combined with the C、D、E. 1. 18-65 years, priority for patients over 30 years; 2. Overweight / obese patients: BMI ≥24 kg/m2. 3. Or combined with nonalcoholic fatty liver disease: determined by the hospital MRI nuclear magnetic quantification; 4. Or combined with dyslipidemia: blood total cholesterol TC≥6.4mmol/L or blood total triglyceride TG≥2.0mmol/L or blood low-density lipoprotein LDL-C≥3.1mmol/L; 5. Or with abnormal blood glucose: * Impaired fasting glucose, IFG: fasting blood glucose was 6.1\ \<7.0mmol/L,and 2 hours after 75g oral blood glucose tolerance test(OGTT) \<7.8mmol / L. * Impaired glucose tolerance, IGT: the fasting blood glucose was \<6.1mmol/L and 2 hours after 75gOGTT was 7.8\ \<11.1 mmol / L; * IFG with IGT: patients with both IFG and IGT; * Patients with type 2 diabetes: random blood glucose 11.1mmol/L or fasting glucose of 7.0 mmol/L or 2 hours after OGTT.
Exclusion criteria
1. Type 2 diabetes and insulin injections or oral hypoglycemic drugs and other special types of diabetes. 2. For women during pregnancy or lactation or with allergies; 3. Patients treated with any hypoglycemic drugs and insulin injections; regular or planned patients taking drugs that may affect glucose and lipid metabolism (as judged by clinicians, such as diet pills, lipid-lowering drugs) and liver protection drugs (as judged by clinicians); 4. Patients with severe cardiovascular diseases, cerebrovascular diseases, liver, kidney, and hematopoietic diseases; 5. Combined with other infectious diseases, such as hepatitis A, hepatitis B, hepatitis C, and acquired immunodeficiency syndrome; 6. Take probiotics, prebiotics, antioxidants and fish oil nutrient supplements within 3 months; 7. Current smokers and regular drinking (excluding social drinkers only); 8. Yogurt intake within 1 week before the first visit and antibiotics within 3 months; 9. Drink strong tea regularly; 10. Participate in other clinical trials within 3 months; 11. Unable not cooperate with the investigator for other reasons. 12. Unfit for the researcherr.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Blood lipids | 0week | Blood lipids were detected by the Roche COBAS C702 biochemical analyzer. |
| Blood glucose | 0week | Blood glucose were detected by the Roche COBAS C702 biochemical analyzer.Normal reference range：Fasting Blood Glucose 3.9-6.1 mmol/L. |
| Hepatic fat fraction indicators | 0week | Siemens 3.0T medical MRI equipment was applied for MAFLD diagnosis and fat quantitative assessment. |
| Intestinal flora detection | 0week | Polymerase Chain Reaction amplification was carried out in the v1-v9 variable region of the 16S rRN gene using universal primer (27F-1492R), and sequencing was conducted in the Illumina novaseq platform. The 16S rRNA amplicon sequence was processed using QIIME2. VSEARCH software was adopted to splice, filter, and remove chimeras from the original sequence to obtain the effective sequences. Clustering was performed according to the 99% similarity of the sequences to obtain the operational taxonomic units (OTU). Based on the Silva NR99 132 database, the representative sequences were analyzed and annotated. The OTU list was generated. The abundance and classification of all OTUs in the samples were recorded. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Bone densitometry | 0 week | The bone mineral density of the axial skeleton (L1-4 vertebrae, left femoral neck, total hip) of the subjects was measured in g/cm2 using a dual-energy X-ray absorptiometry (coefficient of variation \<1%) from Hologic, USA. |
| Alanine aminotransferase | 0week | Creatinine was detected by the Roche COBAS C702 biochemical analyzer. Normal reference range：Alanine aminotransferase: 0-40U/L. |
| Creatinine | 0week | Creatinine was detected by the Roche COBAS C702 biochemical analyzer. Normal reference range：Creatinine: Female 44-97umol/L, Male 53-106umol/L. |
Countries
China
Outcome results
None listed